Request Trial
farmer-3
fotografixx / iStockphoto.com
26 July 2018Biotech

CJEU tightens gene-editing rules with GMO decision

Genome-editing techniques, including CRISPR/Cas9, will be subject to more stringent regulations after a ruling from Europe’s highest court yesterday.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotech
GSK and Moderna settle cross-border patent dispute over vaccine tech
11 November 2026   The parties granted each other the right to use their respective patented inventions in the field of infectious disease but are not obligated to make any payments in connection with the licences.
Biotech
Regeneron and Amgen call a truce on two Eylea biosimilar patents
28 October 2026   Both companies have agreed to dismiss claims and counterclaims involving Amgen’s 2 mg aflibercept biosimilar, while their wider feud continues.
Biotech
10x and Parse set to end sequencing feud after appeals court defeat
23 October 2026   Following the Federal Circuit’s decision to uphold the invalidation of three patents, the parties are set to drop their remaining claims, despite 10x’s separate multi-million dollar jury win.


Editor's picks

In-house counsel rethink patent filing strategies as costs mount
In-house counsel
In-house counsel rethink patent filing strategies as costs mount
3 November 2026

Editor's picks

In-house counsel
In-house counsel rethink patent filing strategies as costs mount
3 November 2026

More features

GSK and Moderna settle cross-border patent dispute over vaccine tech
Eli Lilly follows Novo in UK High Court bid to block ‘black-market websites’
Irish law firms announce merger
How in-house teams can get more value from external counsel
Regulatory and patent teams must align, say Amgen, Genentech, ORIC
EPO starts using AI for minutes but no access to transcripts for parties
LSPN Fall: AI agents are taking on patent work. What’s left for lawyers?
Dykema’s new trademark pro will be a ‘tremendous asset’ to clients